tiprankstipranks
Trending News
More News >
GPI SpA (IT:GPI)
:GPI
Italy Market
Advertisement

GPI SpA (GPI) AI Stock Analysis

Compare
1 Followers

Top Page

IT:GPI

GPI SpA

(GPI)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 4o)
Rating:66Neutral
Price Target:
€18.50
▲(7.31% Upside)
GPI SpA's overall stock score is driven by strong financial performance with significant revenue and profit growth, despite negative free cash flow. The technical analysis indicates bearish momentum, which could pose short-term risks. The valuation is moderate with a reasonable P/E ratio and attractive dividend yield, providing a balanced investment case.
Positive Factors
Revenue Growth
Strong revenue growth indicates effective market penetration and product demand, supporting long-term business expansion and stability.
Profit Margin Improvement
Significant improvement in profit margins reflects enhanced operational efficiency and cost management, contributing to sustainable profitability.
Operational Cash Flow
Improved operational cash flow suggests better cash generation from core activities, enhancing financial flexibility and investment capacity.
Negative Factors
Negative Free Cash Flow
Negative free cash flow can limit financial flexibility and investment in growth opportunities, posing a risk to long-term financial health.
Rising Liabilities
Increasing liabilities may strain the balance sheet and elevate financial risk, potentially impacting the company's ability to manage debt.
Earnings Volatility
Significant volatility in earnings per share growth indicates potential instability in profit generation, affecting investor confidence and valuation.

GPI SpA (GPI) vs. iShares MSCI Italy ETF (EWI)

GPI SpA Business Overview & Revenue Model

Company DescriptionGPI S.p.A. operates in the field of social-healthcare IT services and hi-tech services for healthcare markets. The company offers software solutions for health administration, clinical system, health social care, blood and tissue bank, personnel management, continuum care, public administration, safety and prevention, chronic illness management and patient care, business intelligence and data analytics, health cooperation, and people relationship management. It also provides healthcare administration services, including advanced single booking center system and contract center that reduces the waiting time; advanced healthcare technologies; and health care services. In addition, the company offers Phasys System, a hardware and software solution for medication management in healthcare structures; RIEDL Phasys System for the automation of medicine distribution in pharmacies; ICT services; public administration payment solutions; and retail payment solutions. Further, it provides desktop services, such as design, implementation, and maintenance of technological infrastructure; consultancy and IT assistance; supply of solutions for public administration; help desk services and facility management for local and central PA, healthcare providers, multi-utilities, and private companies; trouble ticketing system; and design of integrated systems. The company was founded in 1988 and is headquartered in Trento, Italy. GPI S.p.A. is a subsidiary of FM S.r.l.
How the Company Makes MoneyGPI generates revenue primarily through the sale of software licenses and IT services tailored for the healthcare sector. The company has a diversified revenue model that includes recurring income from maintenance contracts, subscription services, and consulting fees. Additionally, GPI benefits from partnerships with healthcare institutions and government entities, which provide stable contracts and projects. The company also engages in the development of specialized solutions that address specific needs in the healthcare market, further enhancing its revenue streams. By continuously innovating and expanding its service offerings, GPI positions itself for growth in a market that increasingly relies on digital transformation.

GPI SpA Financial Statement Overview

Summary
GPI SpA demonstrates strong financial health with significant revenue and profit growth, enhanced profitability margins, and a solid balance sheet. Despite negative free cash flow due to high capital expenditures, the company's operational cash generation is improving. Maintaining this trajectory while managing liabilities will be crucial for sustained financial performance.
Income Statement
85
Very Positive
GPI SpA has shown robust revenue growth, with a significant increase from €433.42 million in 2023 to €509.70 million in 2024, reflecting a 17.60% growth rate. The company maintains a strong gross profit margin at 56.60% in 2024, up from 20.93% in 2023, highlighting efficient cost management. The net profit margin improved significantly to 20.41% in 2024 from 1.66% in 2023, indicating enhanced profitability. EBIT and EBITDA margins have also strengthened, at 7.21% and 19.61%, respectively, showcasing improved operational performance.
Balance Sheet
75
Positive
The balance sheet is stable with a debt-to-equity ratio of 0.94, indicating a balanced leverage position. The equity ratio of 32.32% suggests a strong equity base relative to total assets. Return on equity increased to 33.75% in 2024 from 3.09% in 2023, demonstrating efficient use of equity to generate profits. However, the company's total liabilities have grown, which could pose a risk if leverage increases further.
Cash Flow
70
Positive
Operating cash flow has improved to €35.91 million in 2024 from €19.38 million in 2023, indicating stronger cash generation from operations. However, free cash flow remains negative at -€15.48 million due to high capital expenditures. The operating cash flow to net income ratio is 0.35, showing moderate cash generation relative to net income. Continued focus on managing capital expenditures could improve free cash flow position.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue509.70M433.42M346.95M323.89M268.36M
Gross Profit288.52M90.76M246.23M229.57M185.51M
EBITDA99.93M67.96M48.60M47.35M38.65M
Net Income104.04M7.19M9.72M11.05M11.99M
Balance Sheet
Total Assets953.91M855.13M713.24M428.51M414.07M
Cash, Cash Equivalents and Short-Term Investments57.63M41.53M180.92M44.87M81.81M
Total Debt289.63M427.50M262.45M210.51M203.54M
Total Liabilities647.71M623.78M464.29M322.28M330.79M
Stockholders Equity308.33M232.59M248.90M105.06M81.47M
Cash Flow
Free Cash Flow-15.48M20.99M-19.68M-7.89M-3.03M
Operating Cash Flow35.91M39.75M5.58M12.75M10.35M
Investing Cash Flow13.96M-229.95M-64.91M-36.04M-47.61M
Financing Cash Flow-44.77M74.30M195.01M-15.94M32.00M

GPI SpA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price17.24
Price Trends
50DMA
17.56
Negative
100DMA
16.03
Positive
200DMA
12.56
Positive
Market Momentum
MACD
-0.16
Positive
RSI
48.85
Neutral
STOCH
43.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:GPI, the sentiment is Positive. The current price of 17.24 is below the 20-day moving average (MA) of 17.27, below the 50-day MA of 17.56, and above the 200-day MA of 12.56, indicating a neutral trend. The MACD of -0.16 indicates Positive momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 43.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:GPI.

GPI SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
€486.78M22.335.03%11.25%-76.44%
54
Neutral
€16.60M4.81%-260.95%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:GPI
GPI SpA
17.24
6.16
55.60%
IT:HI
Health Italia SpA
287.00
160.50
126.88%
IT:GHC
Garofalo Health Care S.P.A.
5.02
-0.29
-5.48%
IT:EUK
Eukedos S.p.A.
0.72
-0.09
-11.11%
IT:COSMO
Farmacosmo S.P.A.
0.45
-0.15
-25.33%
IT:SVS
Svas Biosana S.p.A.
10.00
3.40
51.52%

GPI SpA Corporate Events

Gpi S.p.A. Announces Strategic Merger of Subsidiaries
Oct 15, 2025

Gpi S.p.A. has announced the signing of merger agreements to incorporate its wholly-owned subsidiaries, Oslo Italia S.r.l. and BIM Italia S.r.l., with legal effects taking place in late 2025 and early 2026. This strategic move is expected to streamline operations and enhance Gpi’s positioning in the healthcare technology sector, potentially benefiting stakeholders by aligning fiscal and accounting effects with the current financial year.

The most recent analyst rating on (IT:GPI) stock is a Buy with a EUR17.50 price target. To see the full list of analyst forecasts on GPI SpA stock, see the IT:GPI Stock Forecast page.

GPI S.p.A. Faces Non-Renewal of Shareholder Agreements
Oct 10, 2025

GPI S.p.A. has announced that FM S.p.A. has decided not to renew the shareholder agreements from the investment agreement signed in June 2022, leading to the agreements lapsing in December 2025. This decision may impact GPI’s operations and stakeholder relationships, as the company will need to address the lapse and its implications in compliance with current legislation.

The most recent analyst rating on (IT:GPI) stock is a Buy with a EUR17.50 price target. To see the full list of analyst forecasts on GPI SpA stock, see the IT:GPI Stock Forecast page.

GPI SpA Reports Strong Growth in H1 2025, Driven by Healthcare Software Focus
Sep 29, 2025

GPI SpA reported strong financial results for the first half of 2025, with a 9.1% increase in revenue and a 14.8% rise in EBITDA, reflecting the success of its strategic focus on software for healthcare digital transformation. The company’s financial position has strengthened due to accelerated invoicing of Consip contracts and recent bond issuances, positioning it for sustainable growth and international expansion.

The most recent analyst rating on (IT:GPI) stock is a Buy with a EUR17.50 price target. To see the full list of analyst forecasts on GPI SpA stock, see the IT:GPI Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 28, 2025